134 related articles for article (PubMed ID: 33899652)
1. 17 Alpha-hydroxyprogesterone caproate use in a rural state.
Ghahremani T; Phillips A; Magann EF; McCoy H; Whittington J; Ounpraseuth S; Eswaran H
J Matern Fetal Neonatal Med; 2022 Dec; 35(25):6437-6439. PubMed ID: 33899652
[TBL] [Abstract][Full Text] [Related]
2. Racial and ethnic disparities in use of 17-alpha hydroxyprogesterone caproate for prevention of preterm birth.
Yee LM; Liu LY; Sakowicz A; Bolden JR; Miller ES
Am J Obstet Gynecol; 2016 Mar; 214(3):374.e1-6. PubMed ID: 26829989
[TBL] [Abstract][Full Text] [Related]
3. Does 17-alpha hydroxyprogesterone caproate prevent recurrent preterm birth in obese women?
Heyborne KD; Allshouse AA; Carey JC
Am J Obstet Gynecol; 2015 Dec; 213(6):844.e1-6. PubMed ID: 26275354
[TBL] [Abstract][Full Text] [Related]
4. 17-Hydroxyprogesterone caproate (17OHP-C) coverage among eligible women delivering at 2 North Carolina hospitals in 2012 and 2013: A retrospective cohort study.
Stringer EM; Vladutiu CJ; Manuck T; Verbiest S; Ollendorff A; Stringer JS; Menard MK
Am J Obstet Gynecol; 2016 Jul; 215(1):105.e1-105.e12. PubMed ID: 26829508
[TBL] [Abstract][Full Text] [Related]
5. 17-hydroxyprogesterone caproate for preterm rupture of the membranes: a multicenter, randomized, double-blind, placebo-controlled trial.
Combs CA; Garite TJ; Maurel K; Abril D; Das A; Clewell W; Heyborne K; How H; Huang W; Lewis D; Lu G; Miller H; Nageotte M; Porreco R; Sheikh A; Tran L;
Am J Obstet Gynecol; 2015 Sep; 213(3):364.e1-12. PubMed ID: 25979614
[TBL] [Abstract][Full Text] [Related]
6. 17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial.
Winer N; Bretelle F; Senat MV; Bohec C; Deruelle P; Perrotin F; Connan L; Vayssière C; Langer B; Capelle M; Azimi S; Porcher R; Rozenberg P;
Am J Obstet Gynecol; 2015 Apr; 212(4):485.e1-485.e10. PubMed ID: 25448515
[TBL] [Abstract][Full Text] [Related]
7. A chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth.
Nelson DB; McIntire DD; Leveno KJ
Am J Obstet Gynecol; 2021 Feb; 224(2):175-186. PubMed ID: 33035472
[TBL] [Abstract][Full Text] [Related]
8. Disparities in 17-Hydroxyprogesterone Caproate Offer and Uptake in Pregnancies at a Risk of Preterm Birth.
Berhie SH; Riley LE; Bryant AS
Am J Perinatol; 2019 Aug; 36(10):1066-1071. PubMed ID: 30508869
[TBL] [Abstract][Full Text] [Related]
9. A Comparison of Vaginal and Intramuscular Progesterone for the Prevention of Recurrent Preterm Birth.
Frey HA; Finneran MM; Hade EM; Waickman C; Lynch CD; Iams JD; Landon MB
Am J Perinatol; 2023 Nov; 40(15):1695-1703. PubMed ID: 34905780
[TBL] [Abstract][Full Text] [Related]
10. Pregnancy duration with use of 17-α-hydroxyprogesterone caproate in a retrospective cohort at high risk of recurrent preterm birth.
Massa K; Childress K; Vricella LK; Boerrigter A; Franklin BHK; Sauer M; Armbruster R; Tomlinson T
Am J Obstet Gynecol MFM; 2020 Nov; 2(4):100219. PubMed ID: 33345927
[TBL] [Abstract][Full Text] [Related]
11. Relation of body mass index to frequency of recurrent preterm birth in women treated with 17-alpha hydroxyprogesterone caproate.
Co AL; Walker HC; Hade EM; Iams JD
Am J Obstet Gynecol; 2015 Aug; 213(2):233.e1-5. PubMed ID: 25912300
[TBL] [Abstract][Full Text] [Related]
12. Patient characteristics associated with 17-alpha hydroxyprogesterone caproate use among a high-risk cohort.
Turitz AL; Bastek JA; Purisch SE; Elovitz MA; Levine LD
Am J Obstet Gynecol; 2016 Apr; 214(4):536.e1-536.e5. PubMed ID: 26519784
[TBL] [Abstract][Full Text] [Related]
13. Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial.
Boelig RC; Schoen CN; Frey H; Gimovsky AC; Springel E; Backley S; Berghella V
Am J Obstet Gynecol; 2022 May; 226(5):722.e1-722.e12. PubMed ID: 35189093
[TBL] [Abstract][Full Text] [Related]
14. Smoking, 17 Alpha-Hydroxyprogesterone Caproate, and Preterm Birth.
Heyborne KD; Allshouse AA
Am J Perinatol; 2016 Oct; 33(12):1191-7. PubMed ID: 27464018
[TBL] [Abstract][Full Text] [Related]
15. 17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.
Nelson DB; McIntire DD; McDonald J; Gard J; Turrichi P; Leveno KJ
Am J Obstet Gynecol; 2017 Jun; 216(6):600.e1-600.e9. PubMed ID: 28223163
[TBL] [Abstract][Full Text] [Related]
16. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.
Ning A; Vladutiu CJ; Dotters-Katz SK; Goodnight WH; Manuck TA
Am J Obstet Gynecol; 2017 Sep; 217(3):371.e1-371.e7. PubMed ID: 28526452
[TBL] [Abstract][Full Text] [Related]
17. Adherence rates and outcomes for 17-hydroxyprogesterone caproate use in women with a previous history of preterm birth.
Edwards AM; Lowry SA; Mikovich S; Forinash AB; Babbar S
Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100166. PubMed ID: 33345885
[TBL] [Abstract][Full Text] [Related]
18. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
[TBL] [Abstract][Full Text] [Related]
19. Factors Associated with Utilization of 17-Hydroxyprogesterone Caproate for the Prevention of Recurrent Preterm Birth.
DeNoble AE; Wynn CE; Weaver KE; Wheeler SM; Swamy GK
Am J Perinatol; 2020 Feb; 37(3):264-270. PubMed ID: 30708392
[TBL] [Abstract][Full Text] [Related]
20. Pregnancy after periviable birth: making the case for innovative delivery of interpregnancy care.
Vani K; Facco FL; Himes KP
J Matern Fetal Neonatal Med; 2019 Nov; 32(21):3577-3580. PubMed ID: 29681199
[No Abstract] [Full Text] [Related]
[Next] [New Search]
